(Picture/Photo from the official website of Global Bio& Investment)
Expand new drugs’ scope and provide customers with full CDMO services.
GBC (CDMO), a major manufacturer of professional sterile injectables, announced at the Asian Bio-Tech Exhibition that it will strengthen its strategic partnership with Alar (6785), a professional developer of P.R. new drugs. GBC carries out the production of clinical drugs for Alar and looks forward to providing Alar with high-quality and cost-competitive drugs through professional sharing and cooperating in R&D and production capacity. The two parties will combine each other's strengths to keep going to cooperate in the development and supply of CDMO for high-tech dosage form for sterile injectables.
Focusing on the development and production of biologics and injectable drugs, GBC is Asia's leading one-stop CDMO service platform, and the only commercial-scale producer in Taiwan covering HPAPIs (High Potent Active Pharmaceutical Ingredients), peptides, macromolecular bio-ingredients and related injectables. GBC is investing on aseptic process and GMP production capacity of the early/rear stage of various types of injectables, and focuses on the development of high-tech level drug production, and has cooperated closely with many large-scale pharm factories and new drug development organizations in Taiwan to provide full-scope CDMO services from small molecules to macromolecules, APIs to injectables, and from pilot-scale for clinical testing to commercial-scale production.
Alar (6785) is a listed company of Emerging, focusing on the development of P.R. injectables for the central nervous system and chronic diseases, and prolonged-release drugs for the treatment of opioid addiction and refractory depression, which have been successively entered into human clinical trials and scale-up production, and have been connected with PIC/S GMP factories. GBC can provide early-stage process parameter optimization, analysis method validation and raw material inspection and quality control services. The two parties have established a complete R&D, scale-up transfer, series integration model and strategy in factory. The current cooperation project products and scope continue to progress, including APIs and sterile injection finished product manufacturing. Some products have entered clinical trials, and the remaining commissioned products are performing preclinical related studies.
With GBC’s biotech manufacture capabilities, high-quality systems, regulatory support and customized services, the GBC team has established strong trust and long-term CDMO partnerships with many new drug development organizations around the world. GBC will continue to assist Alar to promote the development new drugs into the clinical phase III and commercialization as the goal, provide the best quality and cost competitiveness, and jointly bring Taiwan's new drugs into the international market. Maximizing the interests of customers is the highest purpose of GBC.
Read more